Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.37 |
| ▸ | GLP1R | P43220 | 1/20 | 0.33 |
| ▸ | HEXA | P06865 | 1/20 | 0.33 |
| ▸ | HEXB | P07686 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14776060 | 0.85 | L3MBTL1 (0.40) | — | |
| SCHEMBL22623929 | 0.83 | TDP1 (0.39) | — | |
| SCHEMBL9797792 | 0.82 | PDE3B (0.42) | PDE3BPDE3AGLP1RNOS2 | |
| SCHEMBL5419514 | 0.80 | — | — | |
| SCHEMBL23212113 | 0.76 | ALDH1A1 (0.31) | — | |
| SCHEMBL20240844 | 0.76 | HRH1 (0.38) | — | |
| SCHEMBL29364887 | 0.75 | PDE3B (0.39) | PDE3BPDE3ANOS2 | |
| SCHEMBL18641591 | 0.75 | PDE3B (0.39) | PDE3BPDE3ANOS2 | |
| SCHEMBL230258 | 0.74 | PDE4A (0.31) | — | |
| SCHEMBL294405 | 0.73 | PDE3B (0.38) | PDE3BPDE3AGLP1RNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004269-A1 | Pyrazolylmethy Heteroaryl Derivatives | NEUROGEN CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20080004269-A1 | Pyrazolylmethy Heteroaryl Derivatives | NEUROGEN CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20080004269-A1 | Pyrazolylmethy Heteroaryl Derivatives | NEUROGEN CORPORATION | 2008-01-03 | — | — | US | disclosed |
| EP-1807417-A2 | PYRAZOLYLMETHYL HETEROARYL DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006052546-A2 | PYRAZOLYLMETHYL HETEROARYL DERIVATIVES | NEUROGEN CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006052546-A2 | PYRAZOLYLMETHYL HETEROARYL DERIVATIVES | NEUROGEN CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004269-A1 | Pyrazolylmethy Heteroaryl Derivatives | GABBR1, GABRR1, GABRR3 | PDE3B 926/4885PDE3A 500/4885GLP1R 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.